Bear Stearns rates Amgen at peer perform

Amgen Inc. was reiterated at peer perform by Bear Stearns analyst Mark Schoenebaum as the company and Roche file new court documents related to their dispute in Boston District Court. Amgen has requested a May 2007 trial, presumably after CERA, perhaps conceding that it probably can't block a launch through the Boston court. Roche proposed delaying a trial until 2008, according to the analyst. Shares of the Thousand Oaks, Calif.-based biotechnology company were down 64 cents, or 0.88%, at $71.79. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.